新生儿先天性肾上腺皮质增生症生化检查与遗传学检查研究进展
Research Advances in Biochemical and Genetic Testing for Congenital Adrenal Hyperplasia in Neonates
DOI: 10.12677/acm.2025.1572131, PDF,   
作者: 洪文康*, 张 萌:西安医学院研究生部,陕西 西安;张瑞雪, 强 荣, 单 莉#:西北妇女儿童医院医学遗传科,陕西 西安
关键词: 先天性肾上腺皮质增生症新生儿21-羟化酶缺乏症17-羟孕酮Congenital Adrenal Hyperplasia Neonates 21-Hydroxylase Deficiency 17-Hydroxyprogesterone
摘要: 背景:先天性肾上腺皮质增生症(CAH)是一种罕见但严重的遗传性内分泌紊乱疾病。新生儿期大多数CAH临床表现不典型,容易出现漏诊和误诊,而该疾病的诊断主要依赖于生化检查与遗传学检查。目的:该研究的目的是讨论CAH患者的诊断方法中的生化检查与遗传学检查,并简述最新进展。研究CAH的生化检查与遗传学检查,可以更早明确诊断,从而为CAH的患者提供更早期的治疗和管理方案,避免患儿出现严重的并发症。结论:对于临床表现为皮肤色素沉着、外生殖器异常、出现失盐症状等体征的患儿应怀疑CAH并完善17-OHP,ACTH等检查,若清晨直接测量或ACTH兴奋实验后17-OHD > 10 ug/L,可初步诊断为CAH,并尽早行基因检测,明确其临床类型,CAH诊断的金标准为CYP21A2基因突变的分子遗传学检测。
Abstract: Background: Congenital Adrenal Hyperplasia (CAH) is a rare but severe genetic endocrine disorder characterized by abnormal hormone secretion due to adrenal cortex hyperplasia. However, the clinical presentation of CAH in most newborns is atypical, leading to potential misdiagnosis and underdiagnosis. Therefore, accurate early diagnosis is crucial for newborns with congenital adrenal hyperplasia, and the diagnosis mainly relies on biochemical and genetic testing. Objective: The objective of this study is to discuss the biochemical and genetic testing methods in the diagnosis of CAH patients and provide a brief overview of the latest advances. Investigating the biochemical and genetic testing for CAH can lead to an earlier and more accurate diagnosis, thereby providing early treatment and management options for CAH patients and preventing the occurrence of severe complications. Conclusion: For infants exhibiting signs such as skin hyperpigmentation, abnormal external genitalia, and symptoms of salt wasting, suspicion of CAH should arise, and comprehensive evaluations including 17-OHP, ACTH, and other relevant tests should be conducted. If the morning direct measurement or ACTH stimulation test shows 17-OHP > 10 ug/L, a preliminary diagnosis of CAH can be made. Early genetic testing should be performed to determine the clinical type, and the gold standard for CAH diagnosis is molecular genetic testing for CYP21A2 gene mutations.
文章引用:洪文康, 张萌, 张瑞雪, 强荣, 单莉. 新生儿先天性肾上腺皮质增生症生化检查与遗传学检查研究进展[J]. 临床医学进展, 2025, 15(7): 1325-1331. https://doi.org/10.12677/acm.2025.1572131

参考文献

[1] 龚春竹, 程昕然, 鄢力, 李中会, 苟鹏, 唐芳, 苏娜, 冷洁, 汪柳絮, 杜思泓. 新生儿先天性肾上腺皮质增生症28例临床分析[J]. 四川医学, 2021, 42(3): 240-244.
[2] 刘西芳. 新生儿先天性肾上腺皮质增生症的诊疗分析(附43例报告) [D]: [硕士学位论文]. 合肥: 安徽医科大学, 2023.
[3] Miller, W.L. and White, P.C. (2022) History of Adrenal Research: From Ancient Anatomy to Contemporary Molecular Biology. Endocrine Reviews, 44, 70-116. [Google Scholar] [CrossRef] [PubMed]
[4] 罗飞宏. 先天性肾上腺皮质增生症诊断治疗进展[J]. 中华实用儿科临床杂志, 2015, 30(8): 564-569.
[5] 魏玉磊, 杨俊梅, 杨建丽, 解海珍. 17-OHP和ACTH联合检测在新生儿先天性肾上腺皮质增生症早期诊断中的应用研究[J]. 现代医药卫生, 2024, 40(1): 39-42.
[6] 张菊. 26例新生儿先天性肾上腺皮质增生症临床特征分析[J]. 河南医学研究, 2020, 29(33): 6168-6171.
[7] 毛千芊, 谷晓阳. 诸福棠与《诸福棠实用儿科学》[J]. 中国卫生人才, 2023(7): 56-58.
[8] 姜弟棣. 新生儿先天性肾上腺皮质增生症(附4例临床分析) [J]. 新生儿科杂志, 2000, 15(2): 74, 76.
[9] 陶红. 先天性肾上腺皮质增生症的临床与分子遗传学研究[D]: [博士学位论文]. 北京: 中国协和医科大学, 2003.
[10] Pofi, R., Ji, X., Krone, N.P. and Tomlinson, J.W. (2023) Long‐term Health Consequences of Congenital Adrenal Hyperplasia. Clinical Endocrinology, 101, 318-331. [Google Scholar] [CrossRef] [PubMed]
[11] Reddy, N.A., Sharma, S., Das, M., Kapoor, A. and Maskey, U. (2022) Devastating Salt‐Wasting Crisis in a Four‐Month‐Old Male Child with Congenital Adrenal Hyperplasia, Highlighting the Essence of Neonatal Screening. Clinical Case Reports, 10, e6010. [Google Scholar] [CrossRef] [PubMed]
[12] Miller, W.L. and Auchus, R.J. (2011) The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders. Endocrine Reviews, 32, 81-151. [Google Scholar] [CrossRef] [PubMed]
[13] Idkowiak, J., O'Riordan, S., Reisch, N., Malunowicz, E.M., Collins, F., Kerstens, M.N., et al. (2011) Pubertal Presentation in Seven Patients with Congenital Adrenal Hyperplasia Due to P450 Oxidoreductase Deficiency. The Journal of Clinical Endocrinology & Metabolism, 96, E453-E462. [Google Scholar] [CrossRef] [PubMed]
[14] White, P.C. and Speiser, P.W. (2000) Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Endocrine Reviews, 21, 245-291. [Google Scholar] [CrossRef] [PubMed]
[15] Hayashi, G.Y., Carvalho, D.F., de Miranda, M.C., Faure, C., Vallejos, C., Brito, V.N., et al. (2017) Neonatal 17‐Hydroxyprogesterone Levels Adjusted According to Age at Sample Collection and Birthweight Improve the Efficacy of Congenital Adrenal Hyperplasia Newborn Screening. Clinical Endocrinology, 86, 480-487. [Google Scholar] [CrossRef] [PubMed]
[16] Rosenfield, R.L. (2021) Normal and Premature Adrenarche. Endocrine Reviews, 42, 783-814. [Google Scholar] [CrossRef] [PubMed]
[17] 简永建. 新生儿先天性肾上腺皮质增生症筛查诊断实验方法学发展[J]. 中国儿童保健杂志, 2014, 22(10): 1065-1067.
[18] Turcu, A.F., Nanba, A.T., Chomic, R., Upadhyay, S.K., Giordano, T.J., Shields, J.J., et al. (2016) Adrenal-Derived 11-Oxygenated 19-Carbon Steroids Are the Dominant Androgens in Classic 21-Hydroxylase Deficiency. European Journal of Endocrinology, 174, 601-609. [Google Scholar] [CrossRef] [PubMed]
[19] Schröder, M.A.M., Turcu, A.F., O’Day, P., van Herwaarden, A.E., Span, P.N., Auchus, R.J., et al. (2021) Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors. The Journal of Clinical Endocrinology & Metabolism, 107, e272-e280. [Google Scholar] [CrossRef] [PubMed]
[20] Lao, Q., Burkardt, D.D., Kollender, S., Faucz, F.R. and Merke, D.P. (2023) Congenital Adrenal Hyperplasia Due to Two Rare CYP21A2 Variant Alleles, Including a Novel Attenuated CYP21A1P/CYP21A2 Chimera. Molecular Genetics & Genomic Medicine, 11, e2195. [Google Scholar] [CrossRef] [PubMed]
[21] Xu, Z., Chen, W., Merke, D.P. and McDonnell, N.B. (2013) Comprehensive Mutation Analysis of the CYP21A2 Gene: An Efficient Multi-Step Approach to the Molecular Diagnosis of Congenital Adrenal Hyperplasia. The Journal of Molecular Diagnostics, 15, 745-753. [Google Scholar] [CrossRef] [PubMed]
[22] Merke, D.P. and Auchus, R.J. (2020) Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. New England Journal of Medicine, 383, 1248-1261. [Google Scholar] [CrossRef] [PubMed]
[23] 徐钰琪, 林彩娟, 耿国兴, 李威, 阳奇, 罗静思. 391714例新生儿先天性肾上腺皮质增生症筛查与基因检测[J]. 实用医学杂志, 2022, 38(14): 1825-1829.
[24] 中华医学会儿科分会罕见病学组, 中国医师协会医学遗传医师分会, 中国妇幼保健协会出生缺陷防治与分子遗传分会, 上海市医学会分子诊断专科分会, 孙昱, 邬玲仟, 叶蕾, 邱文娟, 余永国. 21羟化酶缺陷导致的先天性肾上腺皮质增生症的实验室诊断共识[J]. 中华医学遗传学杂志, 2023, 40(7): 769-780.
[25] 蔡芸莹, 苏恒. 先天性肾上腺皮质增生症与肾上腺皮质肿瘤的分子遗传学研究进展[J]. 中华临床医师杂志(电子版), 2013, 7(22): 10298-10300.
[26] Clayton, P.E., Miller, W.L., Oberfield, S.E., Ritzén, E.M., Sippell, W.G., Speiser, P.W. and ESPE/LWPES CAH Working Group (2002) Consensus Statement on 21-Hydroxylase Deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Hormone Research, 58, 188-195.
[27] Hannah-Shmouni, F., Morissette, R., Sinaii, N., Elman, M., Prezant, T.R., Chen, W., et al. (2017) Revisiting the Prevalence of Nonclassic Congenital Adrenal Hyperplasia in US Ashkenazi Jews and Caucasians. Genetics in Medicine, 19, 1276-1279. [Google Scholar] [CrossRef] [PubMed]
[28] Gidlöf, S., Falhammar, H., Thilén, A., von Döbeln, U., Ritzén, M., Wedell, A., et al. (2013) One Hundred Years of Congenital Adrenal Hyperplasia in Sweden: A Retrospective, Population-Based Cohort Study. The Lancet Diabetes & Endocrinology, 1, 35-42. [Google Scholar] [CrossRef] [PubMed]
[29] Tseretopoulou, X., Bryce, J., Chen, M., McMillan, M., Lucas‐Herald, A.K., Ali, S.R., et al. (2023) The I‐CAH Registry: A Platform for International Collaboration for Improving Knowledge and Clinical Care in Congenital Adrenal Hyperplasia. Clinical Endocrinology, 101, 397-404. [Google Scholar] [CrossRef] [PubMed]
[30] Held, P.K., Shapira, S.K., Hinton, C.F., Jones, E., Hannon, W.H. and Ojodu, J. (2015) Congenital Adrenal Hyperplasia Cases Identified by Newborn Screening in One-and Two-Screen States. Molecular Genetics and Metabolism, 116, 133-138. [Google Scholar] [CrossRef] [PubMed]